|
[1]
|
王晓卿, 徐钢, 李娟, 等. 淋巴瘤589例构成分析[J]. 临床与实验病理学杂志, 2011, 27(12): 1356-1358. [Google Scholar] [CrossRef]
|
|
[2]
|
Sabattini, E., Bacci, F., Sagramoso, C. and Pileri, S.A. (2010) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2008: An Overview. Pathologica, 102, 83-87.
|
|
[3]
|
李小秋. CD30在淋巴瘤中的表达及检测: 现状与挑战[J]. 中国癌症杂志, 2022, 32(6): 512-518. [Google Scholar] [CrossRef]
|
|
[4]
|
Hoffbrand, A., Catovsky, D., Tuddenham, E., et al. (2010) Appendix II: World Health Organization Classification of Tumours of the Haematopoietic and Lymphoid Tissues.
https://www.who.int/publications/i?publishingoffices=c09761c0-ab8e-4cfa-9744-99509c4d306b
|
|
[5]
|
Falini, B., Pileri, S., Pizzolo, G., et al. (1995) CD30 (Ki-1) Molecule: A New Cytokine Receptor of the Tumor Necrosis Factor Re-ceptor Superfamily as a Tool for Diagnosis and Immunotherapy. Blood, 85, 1-14. [Google Scholar] [CrossRef]
|
|
[6]
|
Slack, G.W., Steidl, C., Sehn, L.H. and Gascoyne, R.D. (2014) CD30 Expression in de novo Diffuse Large B-Cell Lymphoma: A Population-Based Study from British Columbia. British Journal of Haematology, 167, 608-617. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Hu, S., Xu-Monette, Z.Y., Balasubramanyam, A., et al. (2013) CD30 Ex-pression Defines a Novel Subgroup of Diffuse Large B-Cell Lymphoma with Favorable Prognosis and Distinct Gene Expression Signature: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 121, 2715-2724. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Muris, J.J., Meijer, C.J., Vos, W., et al. (2006) Immunohisto-chemical Profiling Based on Bcl-2, CD10 and MUM1 Expression Improves Risk Stratification in Patients with Primary Nodal Diffuse Large B Cell Lymphoma. The Journal of Pathology, 208, 714-723. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Lu, T.X., Gong, Q.X., Wang, L., et al. (2015) Immunohistochemical Algo-rithm Alone Is Not Enough for Predicting the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Clinical and Experimental Pathology, 8, 275-286.
|
|
[10]
|
Iqbal, J., Greiner, T.C., Patel, K., et al. (2007) Dis-tinctive Patterns of BCL6 Molecular Alterations and Their Functional Consequences in Different Subgroups of Diffuse Large B-Cell Lymphoma. Leukemia, 21, 2332-2343. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Davis, R.E., Brown, K.D., Siebenlist, U. and Staudt, L.M. (2001) Con-stitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell-Like Diffuse Large B Cell Lymphoma Cells. Journal of Experimental Medicine, 194, 1861-1874. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Hu, S., Xu-Monette, Z.Y., Tzankov, A., et al. (2013) MYC/BCL2 Protein Coexpression Contributes to the Inferior Survival of Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma and Demonstrates High-Risk Gene Expression Signatures: A Report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 121, 4021-4250. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
贡其星. CD30阳性弥漫大B细胞淋巴瘤的临床病理学研究[D]: [博士学位论文]. 南京: 南京医科大学, 2017.
|
|
[14]
|
陈燕坪, 倪慕兰, 柯龙凤, 等. 伴PAX5拷贝数增加的PAX5阳性间变性大细胞淋巴瘤临床病理特征[J]. 中华病理学杂志, 2022, 51(11): 1155-1157. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Aizawa, S., Nakano, H., Ishida, T., et al. (1997) Tumor Necrosis Factor Receptor-Associated Factor (TRAF) 5 and TRAF2 Are Involved in CD30-Mediated NFκB Ac-tivation. Journal of Biological Chemistry, 272, 2042-2045. [Google Scholar] [CrossRef] [PubMed]
|